{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=18", "query": { "intervention": "Drug A (Blinded Drug)", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 972, "total_pages": 98, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+A+%28Blinded+Drug%29&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:33:36.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01890746", "title": "A Safety and Efficacy Study of Eltrombopag in Subjects With AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukaemia" ], "interventions": [ { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2013-09-05", "completion_date": "2017-01-25", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 14, "location_summary": "Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ames", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01890746" }, { "nct_id": "NCT07107841", "title": "Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Androgenic Alopecia", "Alopecia", "Baldness" ], "interventions": [ { "name": "Autologous Hair Follicle-Derived Secretome", "type": "OTHER" }, { "name": "Placebo Control", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Acorn Biolabs Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2025-10-16", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107841" }, { "nct_id": "NCT02603120", "title": "Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-11-11", "completion_date": "2019-10-23", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 61, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603120" }, { "nct_id": "NCT02072824", "title": "A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Partial Onset Seizures" ], "interventions": [ { "name": "Pregabalin Dose Level 1", "type": "DRUG" }, { "name": "Pregabalin Dose Level 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "3 Years", "sex": "ALL", "summary": "1 Month to 3 Years" }, "enrollment_count": 175, "start_date": "2014-09-16", "completion_date": "2018-03-13", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 5, "location_summary": "Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072824" }, { "nct_id": "NCT00110305", "title": "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278 25 mg", "type": "DRUG" }, { "name": "TMC278 75 mg", "type": "DRUG" }, { "name": "TMC278 150 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2005-06", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 9, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110305" }, { "nct_id": "NCT04629105", "title": "Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ARDS, Human", "Covid19" ], "interventions": [ { "name": "Longeveron Mesenchymal Stem Cells (LMSCs)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Longeveron Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2020-07-24", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 3, "location_summary": "Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629105" }, { "nct_id": "NCT04882124", "title": "Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "CSJ117", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 38, "start_date": "2021-09-24", "completion_date": "2022-09-15", "has_results": false, "last_update_posted_date": "2022-11-28", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 7, "location_summary": "Andalusia, Alabama • Crowley, Louisiana • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Crowley", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882124" }, { "nct_id": "NCT07322146", "title": "Trial of Reducing Inpatient Antibiotic Durations in Children", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pneumonia", "Skin and Soft Tissue (SST) Infection", "Urinary Tract Infections (UTIs)" ], "interventions": [ { "name": "Study Drug Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "60 Days to 17 Years" }, "enrollment_count": 1200, "start_date": "2026-02-13", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322146" }, { "nct_id": "NCT00808665", "title": "Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Spinal Fusion Acquired", "Spinal Stenosis", "Lesions of Lumbosacral Intervertebral Disc", "Spinal Diseases" ], "interventions": [ { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "0.9% Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 68, "start_date": "2009-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808665" }, { "nct_id": "NCT02244619", "title": "PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post-op Pain" ], "interventions": [ { "name": "Oral acetaminophen", "type": "DRUG" }, { "name": "IV acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kettering Health Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2014-09", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-10-15T13:33:36.812Z", "location_count": 1, "location_summary": "Kettering, Ohio", "locations": [ { "city": "Kettering", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244619" } ] }